Edward Imbrogno serves as Chief Financial Officer, Chief Accounting Officer, Vice President - Finance of the Company. From May 2017 to October 2018, Mr. Imbrogno was Senior Director and Corporate Controller for BioDelivery Sciences International, Inc., a Nasdaq-listed specialty pharmaceutical company. From June 2016 to April 2017, Mr. Imbrogno provided accounting and financial reporting consulting services. From September 2013 to May 2014, Mr. Imbrogno was Vice President, Financial Reporting for International Lease Finance Corporation, the world’s largest independent aircraft lessor, until its acquisition by AerCap Holdings N.V. Mr. Imbrogno remained with AerCap through March 2016 assisting with post-acquisition financial reporting transition, primarily at AerCap’s headquarters in Amsterdam, Netherlands. From 2006 to 2013, he was Director, Accounting for Amgena Nasdaq-listed multinational biopharmaceutical company. Prior to Amgen, Mr. Imbrogno held positions at several companies with increasing financial accounting and reporting responsibilities. Mr. Imbrogno began his career in public accounting with EY culminating as an Audit Manager where he provided audit and related financial services to public and private companies. Mr. Imbrogno holds a B.S. in accounting from Pennsylvania State University and an M.B.A. from Wake Forest University. He is a licensed Certified Public Accountant and is a member of the American Institute of Certified Public Accountants.
As the Chief Financial Officer, Chief Accounting Officer и Vice President - Finance of PDL Biopharma Inc, the total compensation of Edward Imbrogno at PDL Biopharma Inc is $814,143. There are 2 executives at PDL Biopharma Inc getting paid more, with Dominique Monnet having the highest compensation of $6,701,000.
Edward Imbrogno is 56, he's been the Chief Financial Officer, Chief Accounting Officer и Vice President - Finance of PDL Biopharma Inc since 2020. There are 3 older and 3 younger executives at PDL Biopharma Inc. The oldest executive at PDL Biopharma Inc is John McLaughlin, 68, who is the Director.
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain и Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
PDL Biopharma Inc executives and other stock owners filed with the SEC include: